Skip to main content
UK clinical trials - updated daily from ClinicalTrials.gov
TrialConnect
← Back to Search
Looking for participantsPhase3

Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight

Sponsor: Eli Lilly and Company

NCT ID: NCT07353931

View on ClinicalTrials.gov ↗

At a glance

What the study gets you
Access to the study treatment being tested
Type of study
Interventional (receives a drug or procedure)
Time in hospital
In-person visits at study sites — visit count not specified by the sponsor
Drug or intervention
Eloralintide (drug), Placebo (drug)
How long the study runs
Study runs about 27 months (dates as stated)
About the drug or intervention
Eloralintide — drug: Administered SC · Placebo — drug: Placebo administered SC
Patient visit burden
Not specified by the sponsor
Type of study
Testing a treatment
Ages
18 Years and over
Who
All
Number of participants
900
Started
2026-02-09
Last checked
2026-10

Plain English Summary

What is this study?

  • • Testing a new treatment for osteoarthritis
  • • Phase3 - 900 participants
  • • The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2

Who can take part?

  • • Ages 18 Years and over
  • • Diagnosed with osteoarthritis

Where?

  • • Bristol - Velocity Clinical Research, Bristol
  • • Glasgow - FutureMeds Glasgow - CPS Research
  • • London - FutureMeds - London
  • • Newcastle - Futuremeds-Newcastle
  • • +4 more UK sites

This is a simplified summary. Always discuss with your doctor before making any decisions.

About This Trial

The YDAN master protocol will support two independent studies, J3R-MC-YOA1 and J3R-MC-YOA2. Each study will investigate how well and safely Eloralintide (LY3841136) works in adults with obesity or overweight who have osteoarthritis (OA) of the knee with pain. Participation in the study will last about 75 weeks, including screening.

OsteoarthritisOverweight or Obesity

How this trial compares with your answers

Answer 2 more questions to improve match

What we know so far

Condition· Matched your search
Age· Tell us your age for better matching
Gender· Tell us your sex for better matching

Still need:

  • • Tell us your age for better matching
  • • Tell us your sex for better matching

Preliminary match based on your answers. Full eligibility requires on-site assessment including medical history, physical exam, and lab tests. This does not guarantee enrolment.

Eligibility at a Glance

Key info

  • Age: 18 Years and over
  • Who can join: All genders

What the study is looking for

  • ✓Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening
  • ✓Have a stable body weight (less than 5% body weight change) for 90 days prior to screening
  • ✓Have tried at least once to lose weight through diet but were unsuccessful
  • ✓Have osteoarthritis of the knee and at least one of the following conditions:
  • ✓Be over 50 years old

Who cannot take part

  • ✗Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if...
  • ✗Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy...
  • ✗Have type 1 diabetes, type 2 diabetes, or any other type of diabetes
  • ✗Have an active knee infection
  • ✗Have had within 90 days prior to screening:
See the full criteria
Inclusion Criteria: * Have a body mass index (BMI) of 27 kilograms per square meter (kg/m²) or higher at screening * Have a stable body weight (less than 5% body weight change) for 90 days prior to screening * Have tried at least once to lose weight through diet but were unsuccessful * Have osteoarthritis of the knee and at least one of the following conditions: * Be over 50 years old * Have morning knee stiffness that lasts about 30 minutes * Have a crackling or grinding sound or feeling in the knee Exclusion Criteria: * Have a prior or planned surgical treatment for obesity (liposuction, cryolipolysis, or abdominoplasty allowed if performed greater than 1 year before screening) * Have a prior or planned endoscopic procedure and/or device-based therapy for obesity (prior device-based therapy acceptable if device removal was more than 6 months prior to screening) * Have type 1 diabetes, type 2 diabetes, or any other type of diabetes * Have an active knee infection * Have had within 90 days prior to screening: * heart attack * stroke * coronary artery revascularization * unstable angina, or * hospitalization due to congestive heart failure * Have a history or diagnosis of New York Heart Association Functional Classification Class IV congestive heart failure * Have taken medications or alternative remedies intended for weight loss within 90 days of screening

Where Is This Study? (8 UK sites)

Velocity Clinical Research, Bristol

Bristol BS8 2RA, United Kingdom

Recruiting
Site contact (verified)
Kirsten PeaceyPrincipal Investigator

FutureMeds Glasgow - CPS Research

Glasgow G20 7BE, United Kingdom

Recruiting
Site contact (verified)
Kristen LaingPrincipal Investigator

FutureMeds - London

London NW10 2PB, United Kingdom

Recruiting
Site contact (verified)
Pembe OzunluPrincipal Investigator

Futuremeds-Newcastle

Newcastle NE6 1SG, United Kingdom

Recruiting
Site contact (verified)
William AspinallPrincipal Investigator

Atlantic Medical

Penzance TR18 3DX, United Kingdom

Recruiting
Site contact (verified)
Alex DewdneyPrincipal Investigator

Woodstock Bower Surgery

Rotherham S61 1AH, United Kingdom

Recruiting
Site contact (verified)
Shahbaz AliPrincipal Investigator

Panthera Biopartners - Sheffield

Sheffield S2 5FX, United Kingdom

Recruiting
Site contact (verified)
Hannah CollinsPrincipal Investigator

Panthera Clinic - York

York YO24 4LJ, United Kingdom

Recruiting
Site contact (verified)
Mahadev RamjeePrincipal Investigator

How to Get in Touch

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or

Sponsor contact

CONTACT

317-615-4559 LillyTrials@Lilly.com

Physicians interested in becoming principal investigators please contact

Sponsor contact

CONTACT

clinical_inquiry_hub@lilly.com
Data sourced from ClinicalTrials.gov · Last verified: 2026-10